Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinton Transition Team Includes Tanden, Underscoring Rx Pricing Focus

Executive Summary

Center for American Progress President Neera Tanden has actively advocated Clinton’s position on prescription drug price controls over the past year.

You may also be interested in...



The Presidential Transition Teams: A Reunion of “Pfizer Pfriends”?

When Hillary Clinton’s transition team was announced last week, much of the coverage focused (appropriately) on the health care experience of one co-chair, Neera Tanden. But another co-chair, former Michigan Governor Jennifer Granholm, also has an interesting history with the largest US pharma company – and, indirectly, with a member of Donald Trump’s transition team.

Clinton Vs. Trump: Three Scenarios For Biopharma

The presidential campaign is about to begin in earnest, and for biopharma companies, the biggest question is what the outcome will mean for the pricing climate in the US. It isn’t an easy question to answer.

Drug Price Control Proposals Pared Down In Democrats’ Draft Platform

Draft includes only a selection of price control policies that have been offered by presumptive nominee Hillary Clinton and candidate Sen. Bernie Sanders on the campaign trail.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS118979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel